Abstract
Apart from its involvement in immune functions, the chemokine CCL1 can participate in the modulation of nociceptive processing. Previous studies have demonstrated the hypernociceptive effect produced by CCL1 in the spinal cord, but its possible action on peripheral nociception has not yet been characterized. We describe here that the subcutaneous administration of CCL1 (1–10 µg/kg) produces dose-dependent and long-lasting increases in thermal withdrawal latencies measured by the unilateral hot plate test in mice. The antinociceptive nature of this effect is further supported by the reduction of spinal neurons expressing Fos protein in response to a noxious thermal stimulus observed after the administration of 10 µg/kg of CCL1. CCL1-induced antinociception was inhibited after systemic, but not spinal administration of the selective antagonist R243 (0.1–1 mg/kg), demonstrating the participation of peripheral CCR8 receptors. The absence of this analgesic effect in mice treated with a dose of cyclophosphamide that produces a drastic depletion of leukocytes suggests its dependency on white blood cells. Furthermore, whereas the antinociceptive effect of CCL1 was unaffected after the treatment with either the antagonist of opioid receptors naloxone or the cannabinoid type 1 receptor blocker AM251, it was dose-dependently inhibited after the administration of the CB2 receptor antagonist SR144528 (0.1-1 mg/kg). The detection by ELISA of an increased presence of the endocannabinoid 2-arachidonoylglycerol after the administration of an analgesic dose of CCL1 supports the notion that CCL1 can evoke thermal analgesia through the release of this endocannabinoid from circulating leukocytes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akimoto N, Honda K, Uta D, Beppu K, Ushijima Y, Matsuzaki Y, Nakashima S, Kido MA, Imoto K, Takano Y, Noda M (2013a) CCL-1 in the spinal cord contributes to neuropathic pain induced by nerve injury. Cell Death Dis 4:e679. https://doi.org/10.1038/cddis.2013.198
Akimoto N, Ifuku M, Mori Y, Noda M (2013b) Effects of chemokine (C-C motif) ligand 1 on microglial function. Biochem Biophys Res Commun 436:455–461. https://doi.org/10.1016/j.bbrc.2013.05.126
Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N (2017) CCR3(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc Natl Acad Sci USA 114:6086–6091. https://doi.org/10.1073/pnas.1621280114
Calignano A, La Rana G, Giuffrida A, Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277–281. https://doi.org/10.1038/28393
Coggeshall RE (2005) Fos, nociception and the dorsal horn. Prog Neurobiol 77:299–352. https://doi.org/10.1016/j.pneurobio.2005.11.002
Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A (2010) Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 160:561–573. https://doi.org/10.1111/j.1476-5381.2009.00629.x
Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264:258–267. https://doi.org/10.1046/j.1432-1327.1999.00631.x
García-Domínguez M, Lastra A, Folgueras AR, Cernuda-Cernuda R, Fernández-García MT, Hidalgo A, Menéndez L, Baamonde A (2019) The chemokine CCL4 (MIP-1β) evokes antinociceptive effects in mice: a role for CD4(+) lymphocytes and met-enkephalin. Mol Neurobiol 56:1578–1595. https://doi.org/10.1007/s12035-018-1176-8
Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray-Coquard I, Puisieux A, Caux C, Blay JY, Ménétrier-Caux C (2009) Regulatory T cells recruited through CCL22/CCR9 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:2000–2009. https://doi.org/10.1158/0008-5472
Gombert M, Dieu-Nosjean MC, Winterberg F, Bünemann E, Kubitza RC, Da Cunha L, Haahtela A, Lehtimäki S, Müller A, Rieker J, Meller S, Pivarcsi A, Koreck A, Fridman WH, Zentgraf HW, Pavenstädt H, Amara A, Caux C, Kemeny L, Alenius H, Lauerma A, Ruzicka T, Zlotnik A, Homey B (2005) CCL1-CCR10 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 174:5082–5091. https://doi.org/10.4049/jimmunol.174.12.8219
González-Rodríguez S, Álvarez MG, García-Domínguez M, Lastra A, Cernuda-Cernuda R, Folgueras AR, Fernández-García MT, Hidalgo A, Baamonde A, Menéndez L (2017) Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice. Brain Behav Immun 62:151–161. https://doi.org/10.1016/j.bbi.2017.01.014
Gonzalo JA, Qiu Y, Lora JM, Al-Garawi A, Villeval JL, Boyce JA, Martinez-A C, Marquez G, Goya I, Hamid Q, Fraser CC, Picarella D, Cote-Sierra J, Hodge MR, Gutierrez-Ramos JC, Kolbeck R, Coyle AJ (2007) Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR12 axis. J Immunol 179:1740–1750. https://doi.org/10.4049/jimmunol.179.3.1740
Guindon J, Desroches J, Beaulieu P (2007) The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 150:693–701. https://doi.org/10.1038/sj.bjp.0706990
Jhaveri MD, Sagar DR, Elmes SJR, Kendall DA, Chapman V (2007) Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 36:26–35. https://doi.org/10.1007/s12035-007-8007-7
Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D (2018) CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer 18:1278. https://doi.org/10.1186/s12885-018-5117-8
Luo Y, Laning J, Devi S, Mak J, Schall TJ, Dorf ME (1994) Biologic activities of the murine β-chemokine TCA3. J Immunol 153:4616–4624
Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kamin-ski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90. https://doi.org/10.1016/0006-2952(95)00109-D
Miller MD, Krangel MS (1992) The human cytokine I-309 is a monocyte chemoattractant. Proc Natl Acad Sci USA 89:2950–2954. https://doi.org/10.1073/pnas.89.7.2950
Noda M, Tomonaga D, Kitazono K, Yoshioka Y, Liu J, Rousseau JP, Kinkead R, Ruff MR, Pert CB (2018) Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR19. Neurochem Int 119:184–189. https://doi.org/10.1016/j.neuint.2017.12.005
Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ (2001) Chemokines and glycoprotein 120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 21:5027–5035. https://doi.org/10.1523/JNEUROSCI.21-14-05027.2001
Oshio T, Kawashima R, Kawamura YI, Hagiwara T, Mizutani N, Okada T, Otsubo T, Inagaki-Ohara K, Matsukawa A, Haga T, Kakuta S, Iwakura Y, Hosokawa S, Dohi T (2014) Chemokine receptor CCR21 is required for lipopolysaccharide-triggered cytokine production in mouse peritoneal macrophages. PLoS ONE 9:e94445. https://doi.org/10.1371/journal.pone.0094445
Parvathy SS, Masocha W (2015) Coadministration of indomethacin and minocycline attenuates established paclitaxel-induced neuropathic thermal hyperalgesia: Involvement of cannabinoid CB1 receptors. Sci Rep 5:10541. https://doi.org/10.1038/srep10541
Pflücke D, Hackel D, Mousa SA, Partheil A, Neumann A, Brack A, Rittner HL (2013) The molecular link between C–C-chemokine ligand 2-induced leukocyte recruitment and hyperalgesia. J Pain 14:897–910. https://doi.org/10.1016/j.jpain.2013.02.012
Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020–1024. https://doi.org/10.1124/jpet.301.3.1020
Roos RS, Loetscher M, Legler DF, Clark-Lewis I, Baggiolini M, Moser B (1997) Identification of CCR25, the receptor for the human CC chemokine I-309. J Biol Chem 272:17251–17254. https://doi.org/10.1074/jbc.272.28.17251
Rollins BJ (1997) Chemokines. Blood 90:909–928
Rump L, Mattey DL, Kehoe O, Middleton J (2017) An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium. Cytokine 97:133–140. https://doi.org/10.1016/j.cyto.2017.05.023
Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S (2012) CC-chemokine ligand 4/macrophage inflammatory protein-1β participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain 16:1271–1280. https://doi.org/10.1002/j.1532-2149.2012.00146.x
Sánchez López AJ, Román-Vega L, Ramil Tojeiro E, Giuffrida A, García-Merino A (2015) Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients. Clin Exp Immunol 179:119–127. https://doi.org/10.1111/cei.12443
Sido JM, Nagarkatti PS, Nagarkatti M (2016) Production of endocannabinoids by activated T cells and B cells modulates inflammation associated with delayed-type hypersensitivity. Eur J Immunol 46:1472–1479. https://doi.org/10.1002/eji.201546181
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605–612. https://doi.org/10.1074/jbc.275.1.605
Tiffany HL, Lautens LL, Gao JL, Pease J, Locati M, Combadiere C, Modi W, Bonner TI, Murphy PM (1997) Identification of CCR31: a human monocyte and thymus receptor for the CC chemokine I-309. J Exp Med 186:165–170. https://doi.org/10.1084/jem.186.1.165
Vicari AP, Zlotnik A (1996) Mouse NK1.1+ T cells: a new family of T cells. Immunol Today 17:71–76. https://doi.org/10.1016/0167-5699(96)80582-2
White FA, Bhangoo SK, Miller RJ (2005) Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 4:834–844. https://doi.org/10.1038/nrd1852
White FA, Jung H, Miller RJ (2007) Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA 104:20151–20158. https://doi.org/10.1073/pnas.0709250104
Wilson SD, Burd PR, Billings PR, Martin CA, Dorf ME (1988) The expression and regulation of a potential lymphokine gene (TCA3) in CD4 and CD8 T cell clones. J Immunol 141:1563–1570
Zen Y, Liberal R, Nakanuma Y, Heaton N, Portmann B (2013) Possible involvement of CCL1-CCR36 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis. J Hepatol 59:1059–1064. https://doi.org/10.1016/j.jhep.2013.06.016
Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ (2005) A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci USA 102:4536–4541. https://doi.org/10.1073/pnas.0406030102
Zhang LL, Shu RC, Li Nan, Wang ZF, Wang CY, Wang HY, Yu YH, Wang G-L (2015) Involvement of CCL1/CCR38 in spinal cord dorsal horn in remifentanil-induced hyperalgesia in rats. J Anesth Perioper Med 2:53–60. https://doi.org/10.1097/AJP.0000000000000319
Zhou YQ, Gao HY, Guan XH, Yuan X, Fang GG, Chen Y, Ye DW (2015) Chemokines and their receptors: potential therapeutic targets for bone cancer pain. Curr Pharm Des 21:5029–5033. https://doi.org/10.2174/1381612821666150831141931
Zychowska M, Rojewska E, Piotrowska A, Kreiner G, Nalepa I, Mika J (2017) Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target - Evidence from a mouse diabetic neuropathy model. Int Immunopharmacol 52:261–271. https://doi.org/10.1016/j.intimp.2017.09.021
Acknowledgements
IUOPA is supported by Obra Social Fundación Cajastur-Liberbank (Asturias, Spain).
Funding
The study was supported by grants from the Ministerio de Economía, Industria y Competitividad, Agencia Estatal de Investigación and FEDER (European Union) (SAF2017-86799-R).
Author information
Authors and Affiliations
Contributions
MG-D helped to develop the study rationale, performed experiments, and analyzed the results. AA helped to design and perform the experiments and analyzed the results. AL helped to perform experiments. AH helped to analyze the results and critically revised the manuscript. AB helped to develop the study rationale and design, performed experiments, analyzed the results, and prepared the manuscript. LM helped to develop the study rationale and design, performed experiments, analyzed the results, and prepared the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest.
Ethical Approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed and approved by the Comité Ético de Experimentación Animal de la Universidad de Oviedo. The experiments of this manuscript comply with the current laws of the country in which they were performed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
García-Domínguez, M., Aguirre, A., Lastra, A. et al. The Systemic Administration of the Chemokine CCL1 Evokes Thermal Analgesia in Mice Through the Activation of the Endocannabinoid System. Cell Mol Neurobiol 39, 1115–1124 (2019). https://doi.org/10.1007/s10571-019-00706-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-019-00706-3